Pharmaceuticals

SSY GROUP

Shisiyao Group Approved as Marketing Authorization Holder for Cefoperazone Sodium Injection

Stone Four Pharma Signs MOU to Acquire Tech and Commercial Rights for Four Biosimilars from Longhai Pharma

Stone Pharmaceutical's Vitamin B12 Injection Gains Approval for New Specifications from NMPA

Stone Pharmaceutical Group Obtains Pharmaceutical Production Registration Approval from China's National Medical Products Administration

Stone Pharmaceutical Group's Furosemide Approved by National Medical Products Administration

Stone Pharmaceutical Group Reports Weakened Operations in 2025 with a Decline in IV Solution Sales

Stone Pharmaceutical's Upadacitinib Approved by National Medical Products Administration

SSY GROUP released FY2025 9 Months earnings on March 27, 2026 (BJT), actual revenue HKD 3.156 B, actual EPS HKD 0.1282

SSY GROUP released FY2025 Q3 earnings on March 27 (BJT), actual revenue HKD 1.009 B, actual EPS HKD 0.032

SSY GROUP released FY2025 Q4 earnings on March 27 Pre-Market (BJT), actual revenue HKD 1.009 B, actual EPS HKD 0.032

SSY GROUP released FY2025 Annual Earnings on March 27 Pre-Market (BJT), actual revenue HKD 4.165 B (forecast HKD 4.458 B), actual EPS HKD 0.1604 (forecast HKD 0.2075)

SSY GROUP to Release FY2025 Annual Earnings on March 27, Pre-Market (BJT), Forecast Revenue HKD 4.458 B, EPS HKD 0.2075

Stone Pharmaceutical Group's Bumetanide Approved by National Medical Products Administration

Stone Pharma Group Obtains Registration Certificates for Two Medical Devices

Sino-Pharm's Two Raw Materials Approved for Market

StoneRain Pharma Obtains Production License for Sodium Phosphoglycerate Injection

Stone Pharmaceutical Obtains Production Registration Approvals for Acetylcysteine Injection and Compound Sodium Lactate Ringer Injection

Stone Pharmaceutical Group Obtains Approval for Fingolimod Active Pharmaceutical Ingredient Registration

SJM Pharmaceutical's Bilastine and Picosulfate Approved by China's NMPA

Stone Pharmaceutical Obtains Production Registration for Tolterodine Tartrate Extended-Release Capsules

SINOFORTUNE FIN

PAN ASIA DATA H

HUASHENG INTL

IMAGI INT'L

SUPERLAND GROUP

QIANHAI HEALTH

STELUX HOLDINGS

JOLIMARK

CASSAVA RES

I-CABLE COMM

02005

SSY Group (HK:2005) purchased 1,000,000 shares on the open market under its Restricted Share Award Scheme using internal resources. This acquisition increases the trustee's holdings to approximately 0.362% of issued share capital, reinforcing long-term incentives for employees and management. The board retains discretion over future awards. Analysts maintain a 'Buy' rating with a HK$5.00 price target.

Tip Ranks

SSY Group Boosts Share Award Pool with Open-Market Purchase

SSY Group disclosed that its restricted share award scheme trustee purchased 2 million shares on the open market on June 23, 2026. The average price was HK$2.16 per share, totaling approximately HK$4.32 million, funded from internal resources. This purchase represents about 0.07% of outstanding shares, increasing the trustee's holding to 9,680,000 shares (0.33%).

PUBT

SSY Group buys 2 million shares for restricted share award scheme at HK$2.16 each

SSY Group (HK:2005) received NMPA approvals for Safinamide Mesylate Tablets for Parkinson's disease and Procaterol Hydrochloride Inhalation Solution for respiratory conditions. These approvals expand the company's portfolio in neurological and therapeutic segments, reinforcing its competitive position in China's generic drug market.

SSY Group Wins NMPA Approvals for Parkinson’s and Respiratory Drugs

SSY Group purchased 380,000 shares at an average price of HK$2.21 per share on June 17, 2026, for its restricted share award plan. The total consideration was approximately HK$840,700, representing about 0.013% of issued share capital. Post-purchase, the trustee's holding increased to 7,680,000 shares, or 0.26% of the issued share capital.

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

SSY Group buys 380,000 shares at HK$ 2.21 each for restricted share award plan

SSY Group has received regulatory approval in China for Oseltamivir Phosphate capsules, enhancing its antiviral portfolio. The company also secured approvals for Drotaverine Hydrochloride and Metoclopramide tablets, expanding its offerings in gastrointestinal and antispasmodic therapies. These developments position SSY Group to benefit from the demand for flu treatments and strengthen its competitive standing in the generic pharmaceutical market. The latest analyst rating for SSY Group (HK:2005) is a Buy with a price target of HK$5.00.

SSY Group Wins Trio of NMPA Approvals, Expanding China Drug Portfolio

SSY Group has received key approvals in China, becoming the first to secure production and registration for a fat-soluble vitamin injection for infants. The company also gained regulatory approvals for metformin hydrochloride tablets and doxazosin mesylate extended release tablets, enhancing its chronic disease portfolio. These developments position SSY Group competitively in the generic drug market. Analysts rate the stock as a Buy with a target price of HK$5.00. SSY Group focuses on developing injectable and oral medications in pediatrics and chronic disease management.

SSY Group Wins Key China Drug Approvals, Expands Chronic and Pediatric Portfolio

01396

02565

02635

03296

02940

02442

01050

03858

00917

GD-HKGBA HLDGS(01396) rose 30.29%, with a trading turnover 255.4 Million HKD, and a year-to-date rose 180.9%. PEGBIO CO-B(02565) rose 13.07%, with a trading turnover 59.8 Million HKD, and a year-to-date fell 59.6%. NUOBIKAN(02635) rose 9.27%, with a trading turnover 47.6 Million HKD, and a year-to-date fell 35.7%.

Top Gainers&Losers

GBA AI COMP

PEGBIO CO-B

NUOBIKAN

HUAQIN

WELLCELL HOLD

EASY SMART GP

KARRIE INT'L

JIAXIN INTL RES

QUNABOX GROUP

Top 10 HK Stock Gainers (5.5)

SSY Group Limited has received Chinese production and registration approval for two cardiovascular injectables: Diltiazem Hydrochloride for Injection and Propranolol Hydrochloride Injection. These approvals enhance the company's portfolio in acute cardiovascular care and strengthen its position in China's hospital drug market. The latest analyst rating for SSY Group (HK:2005) is a Buy with a price target of HK$5.00. The company focuses on developing high-quality injectable drugs for critical care in China.

SSY Group Wins Chinese Approvals for Two Cardiovascular Injectables

520500

588130

588860

159506

520880

560600

512290

159859

SSY Group Limited has received approval from China's National Medical Products Administration for its Upadacitinib bulk drug, a JAK-1 inhibitor for treating autoimmune disorders. This marks the third approval for a PRC entity and is expected to enhance SSY's product portfolio in immunology, improving its competitive position in China's growing market for targeted treatments. The stock currently holds a Hold rating with a price target of HK$3.00 and a market cap of HK$7.08B.

SSY GROUP(02005.HK)